OLEKSANDR HALUSHCHAK / SHUTTERSTOCK.COM
Dolly the Sheep, which would have been 20 this year, raised the possibility of cloning and forced politicians and IP practitioners to address the ethics of the process, with differing results in the US and the UK, as LSIPR reports.
“Should life be patented?” asks Paul Chapman, head of Avidity’s life sciences team, relaying the concern of the UK public and intellectual property officials when the creators of Dolly the Sheep sought to patent their experiment.
Chapman says: “This was in the mid-1990s, a period when the whole issue of the patenting of biotech inventions was very much a hot topic.”
He explains that the cloning, by the scientists Sir Ian Wilmut and Keith Campbell, was an idea had been worked on for a while by the time Dolly became a reality in 1996.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Dolly the Sheep, Avidity, Paul Chapman, patent, trademark, copyright, DNA, transgenic technology, Declaration on Human Cloning, UN,
